HCV NS5B polymerase inhibitors 3: Synthesis and in vitro activity of 3-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-4-hydroxy-2H-quinolizin-2-one derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4484-4487

  Wang, Guangyi ^a   Zhang, Laiguo ^b   Wu, Xiaomin ^b   Das, Debasis ^b   Ruhrmund, Donald ^a   Hooi, Lisa ^a   Misialek, Shawn ^a   Ravi Rajagopalan, P T ^a   Buckman, Brad O ^a   Kossen, Karl ^a   Seiwert, Scott D ^a   Beigelman, Leonid ^a  

^a InterMune Inc   (United States)

^b WUXI APPTEC   (China)

Author keywords

Benzothiadiazine; HCV NS5B polymerase inhibitors

Indexed keywords

3 [1,1 DIOXO 2H (1,2,4) BENZOTHIADIAZIN 3 YL] 4 HYDROXY 2H QUINOLIZIN 2 ONE DERIVATIVE; ANTIVIRUS AGENT; BENZOTHIADIAZINE DERIVATIVE; NONSTRUCTURAL PROTEIN 5B; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; REPLICON;

ANIMALS; ANTIVIRAL AGENTS; BENZOTHIADIAZINES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; MOLECULAR STRUCTURE; QUINOLIZINES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 67649987402     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.021     Document Type: Article

References (14)

1. Shepard C.W., Finelli L., and Alter M.J. Lancet Infect. Dis. 5 (2005) 558
2. WHO, Hepatitis C. Incidence/Epidemiology under Section Surveillance and Control. 2002. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index.html.
3. Manns M.P., Wedemeyer H., and Cornberg M. Gut 55 (2006) 1350
4. Lindenbach B.D., and Rice C.M. Nature 436 (2005) 933
5. Beaulieu P.L. Curr. Opin. Invest. Drugs 8 (2007) 614
6. Rönn R., and Sandström A. Curr. Top. Med. Chem. 8 (2008) 533
7. Tramontano E. Mini-Rev. Med. Chem. 8 (2008) 1298
8. Tedesco R., Shaw A.N., Bambal R., Chai D., Concha N.O., Darcy M.G., Dhanak D., Fitch D.M., Gates A., Gerhardt W.G., Halegoua D.L., Han C., Hofmann G.A., Johnston V.K., Kaura A.C., Liu N., Keenan R.M., Lin-Goerke J., Sarisky R.T., Wiggall K.J., Zimmerman M.N., and Duffy K.J. J. Med. Chem. 49 (2006) 971
9. Krueger A.C., Madigan D.L., Green B.E., Hutchinson D.K., Jiang W.W., Kati W.M., Liu Y., Maring C.J., Masse S.V., McDaniel K.F., Middleton T.R., Mo H., Molla A., Montgomery D.A., Ng T.I., and Kempf D.J. Bioorg. Med. Chem. Lett. 17 (2007) 2289
10. Krueger A.C., Madigan D.L., Jiang W.W., Kati W.M., Liu D., Liu Y., Maring C.J., Masse S., McDaniel K.F., Middleton T., Mo H., Molla A., Montgomery D., Pratt J.K., Rockway T.W., Zhang R., and Kempf D.J. Bioorg. Med. Chem. Lett. 16 (2006) 3367
11. Chen C.M., He Y., Lu L., Lim H.B., Tripathi R.L., Middleton T., Hernandez L.E., Beno D.W.A., Long M.A., Kati W.M., Bosse T.D., Larson D.P., Wagner R., Lanford R.E., Kohlbrenner W.E., Kempf D.J., Pilot-Matias T.J., and Molla A. Antimicrob. Agents Chemother. 51 (2007) 4290
12. Imai Y., Mochizuki A., and Kakimoto M. Synthesis 10 (1983) 851
13. 50 values. Z prime values under these conditions were >0.6.
14. 50 values.